| |
Overall
|
Biologic-naïve
|
1 prior biologic
|
≥ 2 prior biologic
|
|---|
|
N = 225
|
N = 43
|
N = 92
|
N = 90
|
|---|
|
Proportion of days covered during 6-month follow-up
|
|
Mean (SD)
|
0.7 (0.3)
|
0.7 (0.3)
|
0.7 (0.3)
|
0.7 (0.3)
|
|
Median (IQR)
|
0.8 (0.5, 1.0)
|
0.8 (0.5, 1.0)
|
0.9 (0.5, 1.0)
|
0.8 (0.5, 1.0)
|
|
Discontinuation during 4 months of follow-up,a n (%)
|
34 (15.1)
|
9 (20.9)
|
15 (16.3)
|
10 (11.1)
|
|
Time to discontinuation during 4 months of follow-up,a days
|
|
Mean (SD)
|
42.4 (15.0)
|
43.3 (15.8)
|
42.0 (15.2)
|
42.0 (15.5)
|
|
Median (IQR)
|
30.0 (30.0, 60.0)
|
30.0 (30.0, 60.0)
|
30.0 (30.0, 60.0)
|
30.0 (30.0, 60.0)
|
|
Sensitivity analysis (12 months of follow-up)
|
N = 91
|
N = 16
|
N = 31
|
N = 44
|
|---|
|
Proportion of days covered during 12-month follow-up
|
|
Mean (SD)
|
0.7 (0.3)
|
0.8 (0.2)
|
0.7 (0.3)
|
0.6 (0.3)
|
|
Median (IQR)
|
0.8 (0.4, 1.0)
|
0.8 (0.6, 0.9)
|
0.8 (0.5, 1.0)
|
0.6 (0.3, 1.0)
|
|
Discontinuation during 10 months of follow-up,a n (%)
|
36 (39.6)
|
4 (25.0)
|
10 (32.3)
|
22 (50.0)
|
|
Time to discontinuation during 10 months of follow-up,a days
|
|
Mean (SD)
|
120.0 (67.8)
|
177.8 (61.7)
|
131.1 (72.0)
|
104.4 (62.8)
|
|
Median (IQR)
|
99.5 (63.5, 180.0)
|
198.0 (135.0, 220.5)
|
105.5 (90.0, 180.0)
|
94.5 (60.0, 150.0)
|
- The ideal proportion of days covered is 1.0
- IQR, interquartile range; SD, standard deviation
- aPatients were not considered at risk of discontinuing therapy in the last 60 days of their follow-up because of the required 60-day gap to define discontinuation. Therefore, discontinuation was only calculated up to 60 days before the end of the follow-up period
